Genta, Inc.

SAN DIEGO, March 25, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of Syed Rizvi, M.D., as Chief Medical Officer effective April 1, 2024. Dr. Rizvi is a seasoned executive with over 20 years of experience across all stages of drug development, including clinical strategy, execution, and commercialization. "Syed brings to Poseida an impressive combination of industry leadership and highly specialized drug development experience in cell therapy, and I am excited to welcome him to our leadership team during this important period of execution across our clinical stage CAR-T portfolio," said Kristin Yarema, Ph.D., President and Chief Executive Officer of Poseida. "Syed has a proven track record in guiding the development and commercialization of multiple cancer treatments, including three approved autologous CAR-T cell therapies, and his expertise will be an invaluable asset as we usher in the next wave of cell and gene therapies." "Poseida's compelling and proprietary science, impressive manufacturing capabilities, and execution-focused mindset position the Company to bring potentially transformative therapies to patients with significant unmet medical need," said Dr. Rizvi. "I look forward to working with an experienced leadership team to advance Poseida's promising pipeline of allogeneic CAR-T and gene therapy programs at an important and exciting time for the Company." Dr. Rizvi most recently served as Chief Medical Officer of Caribou Biosciences, where he was responsible for overall strategy and execution of all clinical development programs. Prior to joining Caribou, he served as Chief Medical Officer at Chimeric Therapeutics, where he helped build the company's pipeline by licensing programs from leading universities and progressing existing programs through the clinical development process. Dr. Rizvi previously led the development of CARVYKTI®, an approved autologous BCMA CAR-T cell therapy for myeloma, along with other therapies as part of the leadership team at Legend Biotech. Prior to that, he was the global medical head of the CAR-T program at Celgene, where he was responsible for the global medical strategy for both ABECMA® in myeloma and BREYANZI® in lymphoma, supporting the clinical development strategy resulting in approval and potential label expansion into additional indications. Dr. Rizvi previously held global clinical leadership roles of increasing responsibility at Novartis, Merck, and Genta, Inc. Dr. Rizvi received his medical degree from Dow Medical College and spent several years as a physician specializing in hematology and oncology before moving into a clinical research role at St. Vincent's Comprehensive Cancer Center in New York. He has authored multiple scientific publications in peer-reviewed journals and is a member of the American Society of Clinical Oncology, the American Society of Hematology, the American Society for Transplantation and Cellular Therapy, and the European Hematology Association, among other professional organizations. About Poseida Therapeutics, Inc. Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. The Company's pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. The Company's approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ Site-Specific Gene Editing System, Booster Molecule, and nanoparticle and hybrid gene delivery technologies as well as in-house GMP cell therapy manufacturing. The Company has formed a global strategic collaboration with Roche to unlock the promise of cell therapies for patients with hematological malignancies. Learn more at and connect with Poseida on X and LinkedIn. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, expected plans with respect to clinical trials, including timing of regulatory submissions and approvals and clinical data updates; anticipated timelines and milestones with respect to the Company's development programs and manufacturing activities and capabilities; the potential capabilities and benefits of the Company's technology platforms and product candidates; the quotes from Dr. Yarema and Dr. Rizvi; future contributions of the Company's executive officers; the timing of the expected start date of Dr. Rizvi; the Company's ability to exploit and consummate additional business development opportunities; and the Company's plans and strategy with respect to developing its technologies and product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the Company's reliance on third parties for various aspects of its business; risks and uncertainties associated with development and regulatory approval of novel product candidates in the biopharmaceutical industry; the Company's ability to retain key scientific or management personnel; and the other risks described in the Company's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. SOURCE Poseida Therapeutics, Inc.

LEHI, Utah, May 17, 2023 (GLOBE NEWSWIRE) -- CancerVAX, developer of a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer, today reported that the Company’s CEO, Ryan Davies, recently discussed the importance of developing new drugs and medical devices and their impact on the world of healthcare with biotech entrepreneur and venture capitalist Dinesh Patel. Dr. Patel founded TheraTech, a biotech company he took public and later sold to Watson Pharmaceuticals (now Abbvie). He then founded Salus Therapeutics, a biotech company focused on nucleic acid-based therapeutics, including gene therapy drugs and also founded Ashni Natraceuticals. Dr. Patel is the Chairman of the Utah Science Technology and Research Initiative (USTAR). He also serves as Executive Chairman of Xenocor and Chairman of the Board of Light Line Medical (both medical device companies) and is the co-founder and board member of New Eyes. Beyond his extensive career in the biotech space, Dr. Patel is also an active philanthropist actively helping many worthy organizations in the United States. Dr. Patel sits on the board of The Leonardo (a prestigious museum in Salt Lake City) and is a member of the board of the Utah Symphony & Opera. Dr. Patel was a founding partner of v-Spring Capital, a Utah-based venture capital firm active in biotech and high-tech sectors. Dr. Patel also continues to invest on a personal level through Patel Family Investments. “It was a delight speaking with Dinseh. I’ve known and admired him as an investor and biotech entrepreneur for many years,” said Ryan Davies, CancerVAX CEO. “His contributions to the world of medicine and healthcare are remarkable.” The Podcast can be viewed at: https://youtu.be/Um1Ca045Beg For more information about CancerVAX, please visit http:///www.cancervax.com/. About Us CancerVAX, Inc. is a pre-clinical biotechnology company developing a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer. Working with a team of experienced cancer researchers and physicians at UCLA, we intend to create a Universal Cancer Vaccine that will detect, mark, and destroy only the diseased cells with an incredibly high level of precision. Much like the COVID-19 vaccines that train the body to recognize and destroy the coronavirus, our cancer vaccine will leverage the body’s own immune system to destroy cancer cells. As we develop our universal cancer vaccine, we are also working with UCLA to develop single-disease cancer treatments targeting Ewing sarcoma, a rare but deadly bone and soft tissue cancer that primarily affects children and young adults. We look forward to the day when treating cancer will be as simple as getting a flu shot. Forward-Looking Statements This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Press Contact:CancerVAX, Inc.Tel: (805) 356-1810info@CancerVAX.com

CELEBRATION, Fla., Aug. 09, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and lysosomal storage diseases, today announced the appointment of Nichol Ochsner to the role of Vice President, Investor Relations and Corporate Communications. In this newly created position, Ms. Ochsner will be responsible for driving external awareness of KemPharm’s value proposition, including ongoing relations with the Company’s shareholders, covering analysts and prospective investors. “We are very pleased to welcome Nichol to KemPharm and look forward to benefitting from her more than 20 years’ experience developing investor relations and corporate communications strategies in the biopharmaceutical industry,” stated Travis Mickle, Ph.D., President and CEO of KemPharm. “With the addition of arimoclomol, the ongoing advancement of our clinical pipeline, led by KP1077, and the continued commercialization of AZSTARYS®, KemPharm offers multiple opportunities for growth that have appeal to a wide array of stakeholders. Nichol possesses an extensive communications skillset that is ideally suited to positioning such a multifaceted value proposition and conveying our unique vision to the investment community and other constituents.” Prior to joining KemPharm, Ms. Ochsner served as Executive Vice President of Investor Relations and Corporate Communications with Statera Biopharma. Previously, Ms. Ochsner served as Vice President, Investor Relations and Corporate Communications at TherapeuticsMD. Prior to TherapeuticsMD, she was Executive Director, Investor Relations and Corporate Communications at Aralez Pharmaceutical, and, before that, served as Senior Director, Investor Relations and Corporate Communications at Auxilum until its acquisition by Endo International plc for $2.6 billion. Prior to Auxilum, she served as Director of Corporate Communications at Medarex until the acquisition by Bristol Meyers Squibb for $2.4 billion. She has also held positions at Kos Pharmaceuticals, Genta, Enzon Pharmaceuticals and AXA Financial. Ms. Ochchner holds a B.A. in Pre-Law from West Virginia University. “I am very excited to join KemPharm at this important time in the Company’s growth and evolution,” stated Ms. Ochsner. “KemPharm is rare among small biopharmaceutical companies in that it possesses a deep and diverse clinical pipeline coupled with revenue-generating pre-NDA and commercial-stage assets, along with a strong balance sheet. This is a very compelling story, and one that I look forward to showcasing across our continuum of stakeholders.” About KemPharm: KemPharm is a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and lysosomal storage diseases. KemPharm has a diverse product portfolio, combining a clinical-stage development pipeline with revenue-generating NDA-stage and commercial assets. The pipeline includes arimoclomol, an orally-delivered, first-in-class treatment for Niemann-Pick disease type C (NPC), and KP1077, which the company is developing as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy. In addition, the U.S. Food and Drug Administration (FDA) has approved AZSTARYS®, a once-daily treatment for ADHD in patients aged six years and older containing KemPharm’s prodrug, serdexmethylphenidate (SDX), which is being commercialized by Corium, Inc. in the U.S., and APADAZ®, an immediate-release combination product containing benzhydrocodone, KemPharm’s prodrug of hydrocodone, and acetaminophen, which is being commercialized by KVK-Tech, Inc. in the U.S. For more information on KemPharm and its pipeline of product candidates visit or connect with us on Twitter, LinkedIn, Facebook and YouTube. KemPharm Contacts: Tiberend Strategic Advisors, Inc. Jason Rando/Daniel Kontoh-Boateng jrando@tiberend.com dboateng@tiberend.com